74 related articles for article (PubMed ID: 27316374)
1. Racial and Ethnic Variation in Time to Prostate Biopsy After an Elevated Screening Level of Serum Prostate-specific Antigen.
Reading SR; Porter KR; Hsu JY; Wallner LP; Loo RK; Jacobsen SJ
Urology; 2016 Oct; 96():121-127. PubMed ID: 27316374
[TBL] [Abstract][Full Text] [Related]
2. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
3. Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012.
Wallner LP; Hsu JW; Loo RK; Palmer-Toy DE; Schottinger JE; Jacobsen SJ
Urology; 2015 Sep; 86(3):498-505. PubMed ID: 26123517
[TBL] [Abstract][Full Text] [Related]
4. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
Janbaziroudsari H; Mirzaei A; Maleki N
Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
[TBL] [Abstract][Full Text] [Related]
5. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.
Nordström T; Bratt O; Örtegren J; Aly M; Adolfsson J; Grönberg H
Scand J Urol; 2016; 50(2):104-9. PubMed ID: 26625178
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.
Wallner LP; Frencher SK; Hsu JW; Chao CR; Nichol MB; Loo RK; Jacobsen SJ
BJU Int; 2013 Jun; 111(8):1245-52. PubMed ID: 23320750
[TBL] [Abstract][Full Text] [Related]
7. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
8. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy.
Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE
BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
11. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [Abstract][Full Text] [Related]
12. Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?
Doluoglu OG; Ceylan C; Kilinc F; Gazel E; Resorlu B; Odabas O
Int Braz J Urol; 2016; 42(2):346-50. PubMed ID: 27256190
[TBL] [Abstract][Full Text] [Related]
13. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
14. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
16. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
17. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.
Al-Azab R; Toi A; Lockwood G; Kulkarni GS; Fleshner N
Urology; 2007 Jan; 69(1):103-7. PubMed ID: 17270628
[TBL] [Abstract][Full Text] [Related]
18. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
19. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
20. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
Keetch DW; Catalona WJ
J Urol; 1995 Nov; 154(5):1795-7. PubMed ID: 7563349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
